Bajaj Healthcare Earnings Call Transcript: Key Takeaways
Bajaj Healthcare delivered strong H1 growth led by a 82% surge in formulations and key new specialty launches.
- Call
- Guides 15% growth
ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
8 announcements with these filters
Bajaj Healthcare delivered strong H1 growth led by a 82% surge in formulations and key new specialty launches.
Bajaj Healthcare reported Q2 FY27 revenue of ₹175.9 Crore, up 18.9% YoY. EBITDA stood at ₹32.1 Crore, reflecting a 12.2% YoY increase.
Bajaj Healthcare filed its Monitoring Agency Report for the quarter ended September 30, 2026, as required by SEBI regulations for the utilization of preferential issue proceeds.
Bajaj Healthcare Ltd reported revenue from operations of ₹175.9 Cr (+18.9% YoY) and net profit of ₹14.1 Cr (+27.0% YoY) for Q2 FY27.
Bajaj Healthcare received NCLT approval to acquire Genrx Pharmaceuticals Private Limited as a going concern. The entity will become a wholly owned subsidiary.
Bajaj Healthcare Limited has executed a deed of assignment to sell its undertaking located in Dahej Industrial Area, Gujarat, for approximately Rs. 14.67 Crore.
Bajaj Healthcare Limited announced a board meeting on October 17, 2026, to approve the company's un-audited financial results for the quarter and half-year ended September 30, 2026.
Bajaj Healthcare Limited concluded its 33rd Annual General Meeting on September 21, 2026. The shareholders transacted ordinary and special business, including a final dividend declaration.